Exposure to 2009 pH1N1 Vaccine During Pregnancy Seems Safe
Exposure to pH1N1 influenza vaccine in utero not linked to most pediatric health outcomes
Miscellaneous Ob/Gyn Conditions
ProVate Gets FDA Approval to Treat Pelvic Organ Prolapse
The FDA has approved ProVate (ConTIPI) for the temporary, nonsurgical management of pelvic organ prolapse in women.
Generic Version of Hemabate Now Available
The oxytocic agent should be used only with strict adherence to recommended dosages.
Vyleesi Approved for Hypoactive Sexual Desire Disorder
Vyleesi is approved for the treatment of premenopausal women with acquired, generalized, hypoactive sexual desire disorder (HSDD) as characterized by low sexual desire that causes markeddistress or interpersonal difficulty and is not due to: a co-existing medical or psychiatric condition; problems with the relationship; or the effects of a medication or drug substance.
OTC Urethral Support Device Now Available to Treat Stress Urinary Incontinence
An over-the-counter device to treat stress urinary incontinence (SUI) in women has been made available by Rinovum Women’s Health.
DEA Schedules Postpartum Depression Treatment Zulresso
The Drug Enforcement Administration (DEA) has placed Zulresso (brexanolone; Sage Therapeutics), a treatment for postpartum depression, into Schedule IV of the Controlled Substances Act.
Data Insufficient for Safety of Lithium During Breastfeeding
Lithium transfer to infants is variable; three cases of adverse effects reported, but confounding occurred.
Testicular Cancer Treatment Does Not Up Risk for Offspring Birth Defects
No increased risk seen at posttreatment in children of fathers with testicular germ-cell cancer.
A Subpoena and a Case of Patient Privacy, Revisited
This case lingered in the courts for a total of almost 12 years, reaching the state supreme court twice, and set new precedent recognizing a cause of action for patients who have been harmed by the unauthorized disclosure of private medical information.
Early Detection Digital Pregnancy Test Gets FDA Clearance
The Food and Drug Administration (FDA) has cleared the VeriClear Digital Early Result Pregnancy Test (True Diagnostics) which can detect a pregnancy as early as 6 days prior to a missed period.
